clinical trial · NCT07017699
A Study to Assess Deucravacitinib Safety in Pregnancy
Bristol-Myers Squibb·—·recruiting·n = 900
Psoriasis (PsO)DeucravacitinibOther systemic treatments for PsO
brief summary
The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists \[OTIS\]) who were exposed to deucravacitinib.
started
Mar 21, 2025
primary completion
Apr 1, 2028
completion
Feb 28, 2029
last updated
Jun 12, 2025
official title
The Deucravacitinib Pregnancy Exposure Study: A Prospective Observational Study of Deucravacitinib Safety in Pregnancy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol